ALE.P02 for advanced squamous cell cancers with CLDN1
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called ALE.P02 for people with advanced squamous cell cancers (like lung, head and neck, esophagus, or skin cancer) that have a certain protein called CLDN1. The drug is given alone and aims to shrink or stop the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these types of squamous cell cancer: lung, head and neck, esophagus, or skin (including nasopharyngeal cancer).
- Your cancer has come back or spread and cannot be removed by surgery.
- You have already tried at least one standard treatment (like chemo or immunotherapy) and it didn't work or you couldn't tolerate it.
- You are in good enough health to do your daily activities (fully active or able to do light work).
- Your organs (like bone marrow, kidneys, and liver) are working well enough to safely receive the study drug.
- You have a tumor sample that shows a protein called CLDN1 is present.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ALE.P03, for people with advanced or metastatic solid tumors that have a certain protein (CLDN1). The drug is given alone (monotherapy) to see if it can shrink tumors or slow their growth.
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
This is an early-stage trial testing a new drug called CRPA1A2 that trains your immune cells to fight certain cancers. The drug targets tumors that have specific genetic markers (MAGE-A1 and HLA-A*02:01). You may qualify if you have advanced cancer that hasn't responded to standard treatments.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This trial tests a new drug, ALX2004, for people with certain advanced cancers (head and neck, lung, esophagus, or colorectal) that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
Hear when a new Squamous Non-small-cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.